Nitrogen Atoms Occupy 1 And 3- Positions Patents (Class 514/86)
-
Publication number: 20130230480Abstract: There is provided a a sustained release preparation including a dispersion for a sustained release preparation and a volatile active substance, the dispersion having viscosity at 25° C. of not more than 100 mPa·s and including polymer particles which are obtained by polymerizing ethylenically unsaturated group-containing monomers (A), polyvinyl alcohol (C1) in an amount of more than 0% by weight but not more than 30% by weight relative to a total amount of the ethylenically unsaturated group-containing monomers (A), having a degree of saponification of more than 82 mol % but not more than 91.5 mol %, polyvinyl alcohol (C3) in an amount of more than 0% by weight but not more than 30% by weight relative to the total amount of the ethylenically unsaturated group-containing monomers (A), having a degree of saponification of not less than 98 mol %, and water.Type: ApplicationFiled: April 19, 2013Publication date: September 5, 2013Applicant: Nissin Chemical Industry Co., Ltd.Inventors: Ryuichi Saguchi, Takehiko Fukumoto, Masahiko Ikka, Kouji Kinoshita, Hiroyuki Saitou, Yoshihiro Ozawa
-
Publication number: 20130231306Abstract: Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.Type: ApplicationFiled: January 25, 2013Publication date: September 5, 2013Applicant: OSI Pharmaceuticals, LLCInventors: Andrew P. CREW, Dan Sherman, Rama Devi Appari, Xin Chen, Ramesh Chilukuri, Hanqing Dong, Caterina Ferraro, Kenneth Foreman, Ramesh C. Gupta, An-Hu Li, Kathryn M. Stolz, Brian Volk, Robert Zahler
-
Publication number: 20130231307Abstract: Compounds of formula (I) wherein A represents a nucleobase or a derivative thereof, n is equal to 0 or 1 and R?, R? are carbonic chain, and R10 is hydrogen or a carbonic chain for their use as antiviral agents.Type: ApplicationFiled: June 1, 2011Publication date: September 5, 2013Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, KATHOLIEKE UNIVERSITEIT LEUVEN-K.U. LEUVEN R&D, UNIVERSITE DE ORLEANSInventors: Luigi A. Agrofoglio, Vincent Roy, Hugo Pradere, Jan Balzarini, Robert Snoeck, Graciela Andrei
-
Publication number: 20130230481Abstract: There is provided a water dispersion for a sustained release preparation, the dispersion having viscosity at 25° C. of not more than 100 mPa·s and including polymer particles which are obtained by polymerizing ethylenically unsaturated group-containing monomers (A), polyvinyl alcohol (C2) in an amount of more than 0% by weight but not more than 50% by weight relative to a total amount of the ethylenically unsaturated group-containing monomers (A), having a degree of saponification of more than 91.5 mol % and less than 98 mol %, and water. There is also provided a sustained release preparation including the water dispersion and a volatile active substance which is selected from a group consisting of a pheromone substance, an agricultural chemical, an aromatic, a deodorant and an antibacterial agent.Type: ApplicationFiled: April 19, 2013Publication date: September 5, 2013Applicant: Nissin Chemical Industry Co., Ltd.Inventors: Ryuichi Saguchi, Takehiko Fukumoto, Masahiko Ikka, Kouji Kinoshita, Hiroyuki Saitou, Yoshihiro Ozawa
-
Patent number: 8524248Abstract: The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases.Type: GrantFiled: December 15, 2008Date of Patent: September 3, 2013Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Patrick S. Moore, Yuan Chang, Huichen Feng, Christopher Brian Buck, Diana V. Pastrana
-
Publication number: 20130225528Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: ARIAD PHARMACEUTICALS, INC.Inventor: ARIAD Pharmaceuticals, Inc.
-
Publication number: 20130224152Abstract: Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity.Type: ApplicationFiled: February 14, 2013Publication date: August 29, 2013Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventor: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
-
Publication number: 20130225527Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: ARIAD PHARMACEUTICALS, INC.Inventor: ARIAD PHARMACEUTICALS, INC.
-
Patent number: 8518912Abstract: The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).Type: GrantFiled: November 28, 2008Date of Patent: August 27, 2013Assignee: Actelion Pharmaceuticals Ltd.Inventors: Eva Caroff, Kurt Hilpert, Francis Hubler, Emmanuel Meyer, Dorte Renneberg
-
Publication number: 20130195796Abstract: Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.Type: ApplicationFiled: February 18, 2011Publication date: August 1, 2013Applicant: Siga Technologies Inc.Inventors: Robert D. Allen, Sean M. Amberg, Dongcheng Dai, Dennis E. Hruby
-
Publication number: 20130189248Abstract: The application relates to a combination of biologically active compounds comprising at least one antiviral agent and at least one EGFR antagonist, for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of malignant or pre-malignant neoplasms, preferably of solid malignant or pre-malignant neoplasms.Type: ApplicationFiled: March 24, 2011Publication date: July 25, 2013Inventors: Eric Deutsch, Marie Catherine Vozenin, Jean Bourhis
-
Publication number: 20130137661Abstract: Disclosed are compounds useful as gonadotrophin-releasing hormone (“GnRH”) receptor antagonist.Type: ApplicationFiled: November 19, 2010Publication date: May 30, 2013Applicant: SK CHEMICALS CO. LTD.Inventors: Seon Mi Kim, Min Hee Lee, Jae Sun Kim, Hoe Chul Jung, So Young Lee, Soo Min Lee, Eun Jeong Kim, Eui Sun Park, Sung Hoon Park, Bong Yong Lee, Key An Um
-
Publication number: 20130137571Abstract: The present invention relates to a novel crystalline modification of fipronil, to a process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites.Type: ApplicationFiled: January 22, 2013Publication date: May 30, 2013Applicant: BASF SEInventors: Heidi Emilia SAXELL, Peter ERK, Claude TARANTA, Thomas KROEHL, Gerhard COX, Martin SUKOPP, Stefan SCHERER, Antti OJALA, Gautam R. DESIRAJU, Rahul BANERJEE, Prashant M. BHATT
-
Publication number: 20130136776Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.Type: ApplicationFiled: November 27, 2012Publication date: May 30, 2013Applicant: GILEAD PHARMASSET LLCInventor: GILEAD PHARMASSET LLC
-
Publication number: 20130131019Abstract: The present invention relates to novel compounds that contain PNA units substituted with phosphonic acid ester functions or phosphonic acid functions, and have at least one chiral center. The compounds may be used for the treatment of viral diseases, such as AIDS.Type: ApplicationFiled: June 19, 2012Publication date: May 23, 2013Applicant: Ugichem GmbHInventors: Thomas Lindhorst, Birgit Werner, Holger Bock
-
Publication number: 20130121963Abstract: This disclosure relates to novel N-phenyl-2-pyrimidineamines and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering protein-tyrosine kinase inhibitors.Type: ApplicationFiled: May 16, 2012Publication date: May 16, 2013Applicant: Concert Pharmaceuticals Inc.Inventors: Scott L. Harbeson, Julie F. Liu, Roger Tung
-
Publication number: 20130109654Abstract: Artemisinin-derived monomers and artemisinin dimers are shown to exhibit in-vitro anti-cytomegalovirus (CMV) activity. Artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung fibroblasts with no cytotoxicity at concentrations required for complete CMV inhibition. Artemisinin dimers were found to be potent and non-cytotoxic inhibitors of CMV replication, which indicates their use as therapeutic agents for the treatment of CMV infection in humans.Type: ApplicationFiled: December 8, 2010Publication date: May 2, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Ravit Arav-Boger, Gary Posner
-
Patent number: 8426388Abstract: A compound of the formula is disclosed as a prodrug of an HIV protease inhibitor. Methods and compositions for inhibiting HIV protease activity and treating HIV infection are also disclosed.Type: GrantFiled: April 7, 2010Date of Patent: April 23, 2013Assignee: AbbVie Inc.Inventors: David A. DeGoey, William J. Flosi, David J. Grampovnik, Larry L. Klein, Dale J. Kempf, Xiu C. Wang
-
Patent number: 8399433Abstract: Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.Type: GrantFiled: June 1, 2010Date of Patent: March 19, 2013Assignee: OSI Pharmaceuticals, LLCInventors: Rama Devi Appari, Xin Chen, Ramesh Chilukuri, Andrew P. Crew, Hanqing Dong, Caterina Ferraro, Kenneth Foreman, Ramesh C. Gupta, An-Hu Li, Dan Sherman, Kathryn M. Stolz, Brian Volk, Robert Zahler
-
Publication number: 20130065858Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.Type: ApplicationFiled: October 22, 2012Publication date: March 14, 2013Applicants: SUNESIS PHARMACEUTICALS, INC., MILLENNIUM PHARMACEUTICALS, INC.Inventors: MILLENNIUM PHARMACEUTICALS, INC., SUNESIS PHARMACEUTICALS, INC.
-
Publication number: 20130045950Abstract: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.Type: ApplicationFiled: October 4, 2012Publication date: February 21, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: THE REGENTS OF THE UNIVERSITY OF CALIF
-
Publication number: 20130029940Abstract: There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus.Type: ApplicationFiled: October 11, 2012Publication date: January 31, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents of the University of California
-
Patent number: 8362243Abstract: The present invention relates to novel methods for selective localization of active agents both at and in mitochondria within living cells, as well as corresponding active agents that penetrate through the cell membrane into the cells without further adjuvants and there can be localized both at and in mitochondria. These active agents are substituted with at least one monohydroxy mononitrophenyl rest or monohydroxy dinitrophenyl rest.Type: GrantFiled: October 23, 2007Date of Patent: January 29, 2013Assignee: Ugichem Gesellschaft fuer Organische Chemie mbHInventors: Thomas Lindhorst, Birgit Werner, Stefan Piper
-
Publication number: 20130011379Abstract: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.Type: ApplicationFiled: April 13, 2012Publication date: January 10, 2013Applicant: NEPHROGENEX, INC.Inventors: Thorsten Degenhardt, Robert Schotzinger, Wesley J. Fox
-
Publication number: 20120316135Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: wherein the variables are as defined herein.Type: ApplicationFiled: May 4, 2012Publication date: December 13, 2012Applicant: ARIAD Pharmaceuticals, Inc.Inventors: David C. Dalgarno, Wei-Sheng Huang, William C. Shakespeare, Yihan Wang, Xiaotian Zhu
-
Publication number: 20120277192Abstract: The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.Type: ApplicationFiled: December 15, 2010Publication date: November 1, 2012Inventors: Michael D. Altman, Brian M. Andresen, Kenneth L. Arrington, Sathesh Bhat, Jason Burch, Kaleen Konrad Childers, Bernard Cote, Maria Emilia Di Francesco, Anthony Donofrio, Kristina Dupont-Gaudet, John Michael Ellis, Christian Fischer, Jean-Francois Fournier, Jacques Yves Gauthier, Jonathan Grimm, Daniel Guay, David Joseph Guerin, Andrew M. Haidle, Solomon Kattar, Sandra Lee Knowles, Chaomin Li, Jongwon Lim, Michelle R. Machacek, Matthew L. Maddess, Alan B. Northrup, Brendan M. O'Boyle, Ryan D. Otte, Alessia Petrocchi, Michael H. Reutershan, Joel S. Robichaud, Eric Romeo, Adam J. Schell, Tony Siu, Kerrie B. Spencer, Brandon M. Taoka, B. Wesley Trotter, Hyun Chong Woo, Hua Zhou
-
Publication number: 20120277191Abstract: Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs.Type: ApplicationFiled: April 6, 2012Publication date: November 1, 2012Applicant: Johnson Matthey Public Limited CompanyInventors: George Scott Wilson, Angela Barkley, Jurjus Jurayj
-
Publication number: 20120258079Abstract: Methods and pharmaceutical compositions for treating viral infections, by administering certain 2-aryl-benzothiazole or 2-heteroaryl-benzothiazole derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.Type: ApplicationFiled: June 22, 2010Publication date: October 11, 2012Inventors: Chelsea M. Byrd, Dongcheng Dai, Robert Jordan, Dennis E. Hruby
-
Publication number: 20120202776Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.Type: ApplicationFiled: May 21, 2009Publication date: August 9, 2012Applicant: ARIAD Pharmaceuticals, Inc.Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
-
Publication number: 20120184512Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.Type: ApplicationFiled: January 13, 2012Publication date: July 19, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Arnaud Le Tiran, Anne-Laure Grillot, Paul S. Charifson, Yousef Laafiret Bennani, Hardwin O'Dowd, Emanuele Perola
-
Publication number: 20120177681Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.Type: ApplicationFiled: September 1, 2011Publication date: July 12, 2012Inventors: Manmohan Singh, David A.G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
-
Publication number: 20120164104Abstract: The present invention provides methods of treating viral induced tumor or viral infections, including administering a compound described in the invention in a therapeutically effective amount. According to some aspect of the present invention, the methods may further comprise at least one immunosuppressant agent to treat viral infection and/or viral induced tumor to a subject in need of immunosuppressant agents.Type: ApplicationFiled: August 2, 2010Publication date: June 28, 2012Applicant: Chimerix, Inc.Inventors: Ernest Randall Lanier, George R. Painter
-
Publication number: 20120165295Abstract: The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.Type: ApplicationFiled: July 21, 2010Publication date: June 28, 2012Applicant: Chimerix, Inc.Inventors: George R. Painter, Merrick R. Almond
-
Publication number: 20120157412Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: ApplicationFiled: February 28, 2012Publication date: June 21, 2012Inventors: Kathleen A. Battista, Gilles C. Bignan, Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton
-
Publication number: 20120148530Abstract: An inexpensive, easily available, and convenient method of treating or preventing a virus infection is provided. The present invention relates to a method for the treatment or prevention of virus infections using polybiguanide-based compounds administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof The invention relies on the unique biochemical reaction in which polybiguanide-based compounds interfere with the spread of virus within or between organisms. The compositions and formulations described in the present invention are effective means to reduce the infectivity of the human immunodeficiency virus type 1 (HIV-1), and human herpes simplex viruses, and also to kill the causative organisms of many other sexually transmitted diseases (STDs).Type: ApplicationFiled: June 21, 2010Publication date: June 14, 2012Applicant: Novaflux Biosciences, Inc.Inventors: Mohammed E. Labib, Richard F. Stockel
-
Publication number: 20120122680Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein X is O or S; Y is O or S; Z is a direct bond, O, S(O)n, NR6, C(R7)2O, OC(R7)2, C(?X1), C(?X1)E, EC(?X1), C(?NOR8) or C(?NN(R6)2); a is 0, 1, 2 or 3; and R1, R2, R3, R4, R5a, R5b, R6, R7, R8, X1 and E are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.Type: ApplicationFiled: August 3, 2010Publication date: May 17, 2012Applicant: E.I. Du Pont de Nemours and CompanyInventors: Caleb William Holyoke, JR., Wenming Zhang, kanu Maganbhai Patel, George Philip Lahm, My-Hanh Thi Tong
-
Publication number: 20120114624Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein Z is O or S; and R1, R2, R3, Q and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling a parasitic nematode comprising contacting the parasitic nematode or its environment with a biologically effective amount of a compound or a composition of the invention.Type: ApplicationFiled: May 4, 2010Publication date: May 10, 2012Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: George Philip Lahm, Renee M. Lett, Brenton Todd Smith, Benjamin Kenneth Smith, C. Anne Daly
-
Publication number: 20120115815Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: ApplicationFiled: January 19, 2012Publication date: May 10, 2012Applicant: BIOTIE THERAPIES CORP.Inventors: Sirpa JALKANEN, Marko SALMI, Markku JALKANEN
-
Patent number: 8168159Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.Type: GrantFiled: April 3, 2009Date of Patent: May 1, 2012Assignee: President and Fellows of Harvard CollegeInventors: Amin I. Kassis, Ravi S. Harapanhalli
-
Publication number: 20120093729Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: ApplicationFiled: December 19, 2011Publication date: April 19, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Mark D. ERION, K. Raja REDDY, Serge H. BOYER
-
Publication number: 20120087947Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.Type: ApplicationFiled: August 15, 2011Publication date: April 12, 2012Applicant: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20120087904Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Applicant: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20120071447Abstract: Methods, compounds, and pharmaceutical compositions for treating an arenavirus infections are disclosed. Methods for preparing the compounds and pharmaceutical compositions are also disclosed. The novel compounds and compositions are used for treatment of an arenavirus infections, which include but are not limited to the following viruses: Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV.Type: ApplicationFiled: November 10, 2011Publication date: March 22, 2012Applicant: Siga Technologies Inc.Inventors: Dongcheng Dai, Sean M. Amberg, Tove Bolken, Dennis E. Hruby
-
Publication number: 20120064140Abstract: Composite nanogranules from polymer/inorganic nanoparticle, especially first composite nanogranules which are formed from first polymer and inorganic nanoparticles, second composite nanogranules which are obtained by forming second polymer on the first composite nanogranules, third composite nanogranules which is obtained by forming third polymer on the second composite nanogranules, and Nth composite nanogranules which is obtained by forming Nth polymer on the (N?1)th composite nanogranules with the similar method, are disclosed. A composition comprising anyone of the composite nanogranules described above is disclosed. The preparation method thereof and use of the same are also disclosed.Type: ApplicationFiled: May 12, 2010Publication date: March 15, 2012Applicant: Wuxi Now Materials Corp.Inventors: Suping Qian, Yuhong Xu, Zhentian Fan, Yongtal Hou
-
Publication number: 20120058976Abstract: The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of phosphonate ester derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of phosphonate ester derivatives.Type: ApplicationFiled: August 31, 2011Publication date: March 8, 2012Applicant: Chimerix, Inc.Inventors: Roy W. Ware, Merrick R. Almond, Bernhard M. Lampert
-
Patent number: 8114994Abstract: Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.Type: GrantFiled: February 10, 2009Date of Patent: February 14, 2012Assignee: Emory UniversityInventors: Dennis C. Liotta, Shuli Mao, Michael Hager, Raymond F Schinazi
-
Publication number: 20120035135Abstract: The Invention relates to methods for increasing the production potential of plants and/or controlling pests in plants with at least one transgenic modification related to yield increase as compared to a corresponding wild-type plant, comprising treating the location where the plant with at least one transgenic modification is growing or is expected to grow and/or the transgenic plant with at least one transgenic modification or propagation material of the plant with at least one transgenic modification with an effective amount of an insecticidal composition comprising a component A, selected from the group consisting of imidacloprid, thiacloprid, clothianidin, acetamiprid, dinotefuran, nitenpyram, and thiamethoxam; and a component B, selected from the group consisting of fipronil and ethiprole.Type: ApplicationFiled: December 22, 2009Publication date: February 9, 2012Applicant: Bayer CropScience AGInventors: Wolfram Andersch, Heike Hungenberg, Bernd Springer, Stefan Sachau, Casper Isaak Rooijen
-
Publication number: 20120021901Abstract: The present invention relates to novel active compound combinations comprising, firstly, at least one known compound of the formula (I) in which R1 and A have the meanings given in the description and, secondly, at least one further known active compound from the class of the organophosphates or carbamates, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids.Type: ApplicationFiled: March 25, 2009Publication date: January 26, 2012Applicant: BAYER CROPsCIENCE AGInventors: Heike Hungenberg, Peter Jeschke, Robert Velten, Wolfgang Thielert
-
Publication number: 20120010170Abstract: A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conugate compound is CMX001, having formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 25, 2008Publication date: January 12, 2012Inventor: George R. Painter
-
Patent number: 8076347Abstract: (?)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (?)-OddC) or its derivative and its use to treat cancer in animals, including humans.Type: GrantFiled: March 5, 2007Date of Patent: December 13, 2011Assignees: University of Georgia Research Foundation, Inc., Yale UniversityInventors: Chung K. Chu, Yung-chi Cheng